Increased plasma CXCL16 levels in patients with chronic kidney diseases

European Journal of Clinical Investigation

Volumn 41, Issue 8, 2011, Pages 836-845

  Lin, Zhuofeng ^a   Gong, Qi ^b   Zhou, Zhihong ^b   Zhang, Weixing ^b   Liao, Shixian ^b   Liu, Yanlong ^b   Yan, Xinxin ^b   Pan, Xuebo ^b   Lin, Shaoqiang ^b   Li, Xiaokun ^a,b  

^a JINAN UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; CKD; CXCL16; Renal function

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CXCL16 CHEMOKINE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CXCL6; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RECEPTORS, SCAVENGER; REGRESSION ANALYSIS; RENAL DIALYSIS;

EID: 79960105124     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02473.x     Document Type: Article

References (38)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
2. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004;351:1344-6.
3. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005;16:529-38.
4. McClellan WM, Newsome BB, McClure LA, Cushman M, Howard G, Audhya P et al. Chronic kidney disease is often unrecognized among patients with coronary heart disease: the REGARDS Cohort Study. Am J Nephrol 2009;29:10-7.
5. Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? Semin Dial 2004;17:449-54.
6. Himmelfarb J, McMonagle E, Freedman S, Klenzak J, McMenamin E, Le P et al. Oxidative stress is increased in critically ill patients with acute renal failure. J Am Soc Nephrol 2004;15:2449-56.
7. Himmelfarb J. Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol Clin 2005;23:319-30.
8. Okamura DM, Pennathur S, Pasichnyk K, López-Guisa JM, Collins S, Febbraio M et al. CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J Am Soc Nephrol 2009;20:495-505.
9. Kao MP, Ang DS, Pall A, Struthers AD. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 2010;24:1-8.
10. Massy ZA, Stenvinkel P, Drueke TB. The role of oxidative stress in chronic kidney disease. Semin Dial 2009;22:405-8.
11. Bosmans JL, Holvoet P, Dauwe SE, Ysebaert DK, Chapelle T, Jürgens A et al. Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2years. Kidney Int 2001;59:2346-56.
12. Meier P, Spertini F, Blanc E, Burnier M. Oxidized low-density lipoproteins activate CD4+ T cell apoptosis in patients with end-stage renal disease through Fas engagement. J Am Soc Nephrol 2007;18:331-42.
13. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006;26:1702-11.
14. Ruth JH, Haas CS, Park CC, Amin MA, Martinez RJ, Haines GK et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum 2006;54:765-78.
15. Wuttge DM, Zhou X, Sheikine Y, Wågsäter D, Stemme V, Hedin U et al. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004;24:750-5.
16. Zhang L, Ran L, Garcia GE, Wang XH, Han S, Du J et al. Chemokine CXCL16 regulates neutrophil and macrophage infiltration into injured muscle, promoting muscle regeneration. Am J Pathol 2009;175:2518-27.
17. Day C, Patel R, Guillen C, Wardlaw AJ. The chemokine CXCL16 is highly and constitutively expressed by human bronchial epithelial cells. Exp Lung Res 2009;35:272-83.
18. Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 2006;114:583-90.
19. Agostini C, Cabrelle A, Calabrese F, Bortoli M, Scquizzato E, Carraro S et al. Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. Am J Respir Crit Care Med 2005;172:1290-8.
20. Sheikine Y, Sirsjo A. CXCL16/SR-PSOX - a friend or a foe in atherosclerosis? Atherosclerosis 2008;197:487-95.
21. Barlic J, Zhu W, Murphy PM. Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion. J Immunol 2009;182:7928-36.
22. Jansson AM, Aukrust P, Ueland T, Smith C, Omland T, Hartford M et al. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes. Circulation 2009;119:3181-8.
23. Okamura DM, Lopez-Guisa JM, Koelsch K, Collins S, Eddy AA. Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol 2007;293:F575-85.
24. Schramme A, Abdel-Bakky MS, Gutwein P, Obermüller N, Baer PC, Hauser IA et al. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int 2008;74:328-38.
25. Gutwein P, Abdel-Bakky MS, Schramme A, Doberstein K, Kämpfer-Kolb N, Amann K et al. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol 2009;174:2061-72.
26. Devereux RB, Casale PN, Kligfield P, Eisenberg RR, Miller D, Campo E et al. Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol 1986;57:1388-93.
27. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
28. Yang Y, Song M. Hypertension and left ventricular hypertrophy. In: Zhengqiu Y, Shengzhang M, Liangyou Z, editors. Hypertension. Beijing Scientific Publishing Company; 2000: pp 1428-41.
29. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57:1246-53.
30. Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem 2004;279:3188-96.
31. Shimaoka T, Nakayama T, Fukumoto N, Kume N, Takahashi S, Yamaguchi J et al. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol 2004;75:267-74.
32. Shimaoka T, Nakayama T, Kume N, Takahashi S, Yamaguchi J, Minami M et al. Cutting edge: SR-PSOX/CXC chemokine ligand 16 mediates bacterial phagocytosis by APCs through its chemokine domain. J Immunol 2003;171:1647-51.
33. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 2004;172:3678-85.
34. Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007;179:7166-75.
35. Gutwein P, Abdel-Bakky MS, Doberstein K, Schramme A, Beckmann J, Schaefer L et al. CXCL16 and oxLDL are induced in the onset of diabetic nephropathy. J Cell Mol Med 2009;13:3809-25.
36. Lu C, Gao Y, Zhou H, Tian H. The relationships between PON1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose. Coron Artery Dis 2008;19:565-73.
37. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005;112:651-7.
38. Lezaic V, Tirmenstajn-Jankovic B, Bukvic D, Vujisic B, Perovic M, Novakovic N et al. Efficacy of hyperphosphatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification. Clin Nephrol 2009;71:21-9.